CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Online 1-Day Cognitive Behavioural Therapy (CBT)-Based WorkshopWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D019052 Depression, Postpartum NIH 0.38
D003863 Depression, NIH 0.14

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Online 1-Day CBT-Based Workshops for Postpartum Depression

Postpartum depression (PPD) already affects up to 1 in 5 women and left untreated costs $150,000 per case over the lifespan. Under normal conditions, just 10% of women with PPD get evidence-based treatment, a situation that has worsened substantially during COVID-19. The purpose of this study is to a assess if self-referred, online adaptation of a 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop for PPD delivered up to 30 women at a time can lead to reductions in PPD, if the workshops are cost-effective, and to assess workshop impact on common complications of PPD (anxiety, partner relationship discord, problems with mother-infant attachment). 334 women will be randomized to receive either immediate treatment or treatment 12 weeks later (waitlist control). Study measures will be collected at baseline (immediately before treatment workshop) and 12 weeks later (immediately before wait list control workshop).

NCT04485000 Postpartum Depression Behavioral: Online 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop
MeSH:Depression, Postpartum Depression

Primary Outcomes

Description: The gold standard measure of PPD in clinical practice/research. A change of 4 points is recognized as a clinically meaningful/significant improvement.

Measure: Edinburgh Postnatal Depression Scale (EPDS)

Time: Differences between experimental and control groups from T1 (baseline) to T2 (12 weeks) will be compared.

Secondary Outcomes

Description: Healthcare resource utilization data will be collected using a questionnaire based on the Canadian Community Health Survey and the Service Use and Resources Form adapted for the postpartum period and used in previous PPD research. Costs will be calculated using provincial or other standard billing rates.

Measure: Cost-effectiveness: Costs of service

Time: Resources consumed over the 12-week trial period from the perspective of public healthcare payer will be measured.

Description: The EQ-5D-5L, a utility-based health-related quality of life instrument will be used. Its validity in measuring the impact of depression is established. Its Canadian scoring algorithm will be used. For each participant, a QALY will be calculated by multiplying the health utility for the matching time period (i.e., the area under the curve approach).

Measure: Cost-effectiveness: Quality-Adjusted Life Year (QALY)

Time: QALYs will be measured over the 12-week trial period.

Other Outcomes

Description: A 7-item self-report scale of symptoms of generalized anxiety disorder, the most common PPD comorbidity.

Measure: Generalized Anxiety Disorder-7 (GAD-7)

Time: 12 weeks

Description: 25-item maternal-report scale of mother-infant attachment.

Measure: Postpartum Bonding Questionnaire

Time: 12 weeks

Description: The SPS is a 24-item self-report measures of the degree to which an individual's social relationships provide support.

Measure: Social Provisions Scale

Time: 12 weeks

Description: A 37-item meausure of infant behavior and temperament.

Measure: Infant Behavior Questionnaire - Revised (Very Short Form)

Time: 12 weeks

Description: Differences between experimental and control groups from T1 (baseline) to T2 (12 weeks) will be compared.

Measure: Beck Depression Inventory-II (BDI-II)

Time: 12 weeks

No related HPO nodes (Using clinical trials)